IL269879B2 - Combination therapy for prostate cancer - Google Patents

Combination therapy for prostate cancer

Info

Publication number
IL269879B2
IL269879B2 IL269879A IL26987919A IL269879B2 IL 269879 B2 IL269879 B2 IL 269879B2 IL 269879 A IL269879 A IL 269879A IL 26987919 A IL26987919 A IL 26987919A IL 269879 B2 IL269879 B2 IL 269879B2
Authority
IL
Israel
Prior art keywords
niraparib
abiraterone acetate
patient
use according
administering
Prior art date
Application number
IL269879A
Other languages
English (en)
Hebrew (he)
Other versions
IL269879A (https=
IL269879B1 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL269879(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL269879A publication Critical patent/IL269879A/en
Publication of IL269879B1 publication Critical patent/IL269879B1/en
Publication of IL269879B2 publication Critical patent/IL269879B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IL269879A 2017-04-13 2018-04-09 Combination therapy for prostate cancer IL269879B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Publications (3)

Publication Number Publication Date
IL269879A IL269879A (https=) 2019-11-28
IL269879B1 IL269879B1 (en) 2025-06-01
IL269879B2 true IL269879B2 (en) 2025-10-01

Family

ID=62067858

Family Applications (2)

Application Number Title Priority Date Filing Date
IL269879A IL269879B2 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer
IL320452A IL320452A (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL320452A IL320452A (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Country Status (33)

Country Link
US (4) US20180296574A1 (https=)
EP (3) EP4176878A1 (https=)
JP (3) JP7141408B2 (https=)
KR (2) KR20260048358A (https=)
CN (2) CN110753545A (https=)
AU (2) AU2018251594A1 (https=)
CA (1) CA3059562A1 (https=)
CL (1) CL2019002871A1 (https=)
CO (1) CO2019011591A2 (https=)
CR (1) CR20190467A (https=)
DK (1) DK3609497T3 (https=)
DO (1) DOP2019000264A (https=)
EA (1) EA201992430A1 (https=)
ES (1) ES2931052T3 (https=)
HR (1) HRP20221327T1 (https=)
HU (1) HUE060460T2 (https=)
IL (2) IL269879B2 (https=)
JO (2) JOP20190244B1 (https=)
LT (1) LT3609497T (https=)
MA (1) MA48728B1 (https=)
MD (1) MD3609497T2 (https=)
MX (2) MX2019012296A (https=)
MY (1) MY209010A (https=)
NI (1) NI201900105A (https=)
PE (1) PE20200444A1 (https=)
PH (1) PH12019502317A1 (https=)
PL (1) PL3609497T3 (https=)
PT (1) PT3609497T (https=)
RS (1) RS63832B1 (https=)
SG (1) SG11201909552VA (https=)
SM (1) SMT202200467T1 (https=)
UA (1) UA129514C2 (https=)
WO (1) WO2018191141A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124972C2 (uk) 2016-07-29 2021-12-22 Янссен Фармацевтика Нв Способи лікування раку передміхурової залози
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
TWI905184B (zh) * 2020-05-08 2025-11-21 比利時商健生藥品公司 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌
WO2022200982A1 (en) * 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PL2478907T3 (pl) * 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
KR101653548B1 (ko) 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS:, NCT00485303, 25 June 2013 (2013-06-25) *
ANONYMOUS:, NCT01576172, 23 December 2016 (2016-12-23) *
GRAS J.,, NIRAPARIB HYDROCHLORIDE POLY [ADP-RIBOSE] POLYMERASE (PARP) INHIBITOR, ONCOLYTIC, 31 October 2013 (2013-10-31) *
HUSSAIN M. ET AL.:, CO-TARGETING ANDROGEN RECEPTOR (AR) AND DNA REPAIR: A RANDOMIZED ETS GENE FUSION-STRATIFIED TRIAL OF ABIRATERONE + PREDNISONE (ABI) +/- THE PARP1 INHIBITOR VELIPARIB FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) (NCI9012), 20 May 2016 (2016-05-20) *
MURAI J. ET AL.:, DIFFERENTIAL TRAPPING OF PARP1 AND PARP2 BY CLINICAL PARP INHIBITORS, 1 November 2012 (2012-11-01) *
PINK SHEET DAILY:, MONETIZING FOCUS: TESARO ADDS RUNWAY BY OUT-LICENSING NIRAPARIB IN PROSTATE CANCER, 6 April 2016 (2016-04-06) *
R. J. AUCHUS ET AL,, USE OF PREDNISONE WITH ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 31 October 2014 (2014-10-31) *

Also Published As

Publication number Publication date
EP3609497B1 (en) 2022-10-12
RS63832B1 (sr) 2023-01-31
KR20190134718A (ko) 2019-12-04
JP7407880B2 (ja) 2024-01-04
PL3609497T3 (pl) 2023-01-23
JP2022141881A (ja) 2022-09-29
MX2019012296A (es) 2019-11-28
PT3609497T (pt) 2023-01-23
MX2023009569A (es) 2023-08-22
JP2024023344A (ja) 2024-02-21
NI201900105A (es) 2020-03-11
US20240245710A1 (en) 2024-07-25
JOP20190244A1 (ar) 2019-10-13
UA129514C2 (uk) 2025-05-21
IL320452A (en) 2025-06-01
US20240398837A1 (en) 2024-12-05
PE20200444A1 (es) 2020-02-28
MD3609497T2 (ro) 2023-03-31
MA48728A (fr) 2020-04-08
MY209010A (en) 2025-06-16
CL2019002871A1 (es) 2019-12-27
CO2019011591A2 (es) 2020-02-28
EA201992430A1 (ru) 2020-02-28
JP2020516646A (ja) 2020-06-11
PH12019502317A1 (en) 2020-07-06
ES2931052T3 (es) 2022-12-23
WO2018191141A1 (en) 2018-10-18
CN110753545A (zh) 2020-02-04
SG11201909552VA (en) 2019-11-28
MA48728B1 (fr) 2022-10-31
HUE060460T2 (hu) 2023-03-28
JOP20230159A1 (ar) 2023-07-13
DK3609497T3 (da) 2022-10-31
AU2024202346A1 (en) 2024-05-02
AU2024202346B2 (en) 2026-01-22
US20220175801A1 (en) 2022-06-09
AU2018251594A1 (en) 2019-10-24
JP7141408B2 (ja) 2022-09-22
IL269879A (https=) 2019-11-28
US20180296574A1 (en) 2018-10-18
CA3059562A1 (en) 2018-10-18
BR112019021466A2 (pt) 2020-05-12
CN119235874A (zh) 2025-01-03
CR20190467A (es) 2020-03-09
SMT202200467T1 (it) 2023-01-13
LT3609497T (lt) 2022-12-12
IL269879B1 (en) 2025-06-01
EP3609497A1 (en) 2020-02-19
EP4176878A1 (en) 2023-05-10
JOP20190244B1 (ar) 2024-04-18
DOP2019000264A (es) 2020-07-15
HRP20221327T1 (hr) 2023-03-17
KR20260048358A (ko) 2026-04-09
EP4176879A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
AU2024202346B2 (en) Combination therapy for prostate cancer
Paridaens et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
JP7569353B2 (ja) 前立腺癌の治療方法
JP2019011376A (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
JP2024510612A (ja) ソトラシブ投与レジメン
JP2022518235A (ja) 進行期固形腫瘍がんの治療用ｒｎａ
HK40092155A (en) Combination therapy for prostate cancer
EA052155B1 (ru) Комбинированная терапия рака предстательной железы
EA044835B1 (ru) Комбинированная терапия рака предстательной железы
BR122022022077B1 (pt) Combinação e composição compreendendo niraparibe, acetato de abiraterona, e prednisona, seu uso para tratar câncer de próstata e kit
BR112019021466B1 (pt) Composição compreendendo niraparibe, acetato de abiraterona, e prednisona, bem como uso dos referidos compostos
HK40126976A (en) Methods of treating prostate cancer
AU2023214795A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
CA3223426A1 (en) Treatment of metastatic castration-resistant prostate cancer with niraparib